Leukemia research

Keyphrases

Publications

volume 136, 2023

Riley Karpen, Jeremy Sen, Sarah Wall, Samantha Musson, Justin Tossey
Evaluation of palonosetron, fosaprepitant, and olanzapine as antiemetic prophylaxis for fludarabine and melphalan-based conditioning regimens prior to allogeneic hematopoietic stem cell transplants. Leukemia research 136 (2023)
Michael Ashby, Shaun Fleming, Tse-Chieh Teh, Ing Soo Tiong, Shafqat Inam, David J Curtis, Sushrut Patil, Catherine Vassili, Chong Chyn Chua
Low-intensity venetoclax-based salvage as a bridge to allogeneic stem cell transplant in patients with acute myeloid leukemia failing conventional intensive chemotherapy. Leukemia research 136 (2023)
Carlo Pescia, Gianluca Lopez, Daniele Cattaneo, Cristina Bucelli, Umberto Gianelli, Alessandra Iurlo
The molecular landscape of myeloproliferative neoplasms associated with splanchnic vein thrombosis: Current perspective. Leukemia research 136 (2023)

volume 135, 2023

A B Notarantonio, G Roth-Guépin, C Bonmati, M Divoux, C Kicki, S Pagliuca, A Campidelli, M T Rubio, M D'Aveni-Piney
A new sequential conditioning regimen based on CPX- 351/Vyxeos ("Vyx-Seq") in patients with higher risk myelodysplastic syndromes. Leukemia research 135 (2023)
Aditya Ravindra, Luna Acharya, Bradley Loeffler, Sarah Mott, Grerk Sutamtewagul, Prajwal Dhakal
Venetoclax-based therapy in treatment-naïve and relapsed/refractory acute myeloid leukemia. Leukemia research 135 (2023)
Qinqiao Lai, Yan Zhao, Haiqing Yan, Hongling Peng
Advances in diagnosis, treatment and prognostic factors of gastrointestinal DLBCL. Leukemia research 135 (2023)
Carlos Jiménez-Vicente, Alexandra Martínez-Roca, Helena Pomares, Sandra Castaño-Diez, Francesca Guijarro, Mònica López-Guerra, Alex Bataller, Daniel Esteban, Albert Cortés-Bullich, Amanda Isabel Pérez-Valencia, Ares Guardia-Torrelles, Inés Zugasti, Montserrat Rovira, Francesc Fernández-Avilés, Dolors Colomer, Montserrat Arnan, Marina Díaz-Beyá, Jordi Esteve
Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF. Leukemia research 135 (2023)
J Scott Beeler, Kelly L Bolton
How low can you go?: Methodologic considerations in clonal hematopoiesis variant calling. Leukemia research 135 (2023)
Fan Zhang, Hongmin Du, Chenxi Hu, Yongping Song
A new prognostic risk model for acute myeloid leukemia patients based on telomere-related genes. Leukemia research 135 (2023)
Faezeh Ansari, Maryam Behfar, Leila Jafari, Rashin Mohseni, Parisa Naji, Yalda Karamlou, Mohammad Hossein Amirzade-Iranaq, Amir Ali Hamidieh
A comprehensive comparison between TBI vs non-TBI-based conditioning regimen in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis. Leukemia research 135 (2023)

volume 134, 2023

Ian M Bouligny, Graeme Murray, Thuy Ho, Michael Doyel, Tilak Patel, Josh Boron, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer, Kyle Zacholski, Chad Venn, Nolan A Wages, Steven Grant, Keri R Maher
Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia. Leukemia research 134 (2023)
Afshin Shameli, Poonam Dharmani-Khan, Iwona Auer, Meer-Taher Shabani-Rad
Deep immunophenotypic analysis of the bone marrow progenitor cells in myelodysplastic syndromes. Leukemia research 134 (2023)
Tamanna Haque, Felix López Cadenas, Blanca Xicoy, Ana Alfonso-Pierola, Uwe Platzbecker, Irit Avivi, Andrew M Brunner, Jöerg Chromik, Daniel Morillo, Manish R Patel, Jose Falantes, Heather A Leitch, Ulrich Germing, Meir Preis, Laurie Lenox, Josh Lauring, Regina J Brown, Anna Kalota, Jaydeep Mehta, Friederike Pastore, Junchen Gu, Pankaj Mistry, David Valcárcel
Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes. Leukemia research 134 (2023)
Gunnar Larfors, Daniel Moreno Berggren, Hege Garelius, Lars Nilsson, Bengt Rasmussen, Eva Hellström-Lindberg, Elisabeth Ejerblad
MDS-Comorbidity Index using register data has prognostic impact in Swedish MDS patients. Leukemia research 134 (2023)
Mark Gurney, Patricia T Greipp, Troy Gliem, Ryan Knudson, Aref Al-Kali, Naseema Gangat, Terra Lasho, Abhishek A Mangaonkar, Christy M Finke, Mrinal M Patnaik
TET2 somatic copy number alterations and allelic imbalances in chronic myelomonocytic leukemia. Leukemia research 134 (2023)
Shyam A Patel, Elisa Bello, Andrew Wilks, Jonathan M Gerber, Narayanan Sadagopan, Jan Cerny
Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations. Leukemia research 134 (2023)
Victoria M Rogness, Wei Wei, Matthew Cortese, Brian T Hill
Impact of active surveillance at time of diagnosis on overall survival in nodular lymphocyte-predominant Hodgkin lymphoma: A National Cancer Database study. Leukemia research 134 (2023)
Sumukh Arun Kumar, Jenny Gao, Shyam A Patel
The shifting therapeutic paradigm for relapsed/refractory mantle cell lymphoma. Leukemia research 134 (2023)
Kei Nakajima, Megumi Suzuki, Ichiro Kawashima, Megumi Koshiisi, Takuma Kumagai, Takeo Yamamoto, Masaru Tanaka, Keita Kirito
The chaperone protein GRP78 released from MPN cells increases the expression of lysyl oxidase in a human stromal cell line. Leukemia research 134 (2023)
Omer Hassan Jamy, Margaret Kasner, Sarah Wall, Stacey Ingram, D 'Ambra Dent, William N Dudley, Leah Dudley, Julie M Scott, Debra Wujcik
Integrating electronic geriatric assessment and frailty screening for adults with acute myeloid leukemia to drive personalized treatment decisions. Leukemia research 134 (2023)
Davidson Zhao, Qianghua Zhou, Mojgan Zarif, Entsar Eladl, Cuihong Wei, Eshetu G Atenafu, Andre Schuh, Anne Tierens, Yu Wing Tony Yeung, Mark D Minden, Hong Chang
AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts. Leukemia research 134 (2023)
Charanpreet Singh, Parathan Karunakaran, Uday Yanamandra, Nishant Jindal, Saloni Rani Kumar, Neha Saini, Aditya Jandial, Arihant Jain, Deepesh Lad, Gaurav Prakash, Alka Khadwal, Narender Kumar, Shano Naseem, Jasmina Ahluwalia, Neelam Varma, Subhash Varma, Pankaj Malhotra
Factors associated with thrombo-hemorrhagic deaths in patients with Acute Promyelocytic leukemia treated with Arsenic Trioxide and all-trans retinoic acid. Leukemia research 134 (2023)
Swe Mar Linn, Igor Novitzky-Basso, Christopher Patriquin, Ivan Pasic, Wilson Lam, Arjun Law, Fotios V Michelis, Armin Gerbitz, Auro Viswabandya, Jeffrey Lipton, Rajat Kumar, Jonas Mattsson, David Barth, Dennis Dong Hwan Kim
Single centre retrospective analysis of extracorporeal photopheresis (ECP) therapy in patients heavily pre-treated for chronic graft-versus-host disease (cGvHD) with steroid failure. Leukemia research 134 (2023)

volume 133, 2023

Fernando De la Garza-Salazar, Perla Rocío Colunga-Pedraza, David Gómez-Almaguer, Valeria Abigail García-Zárate, Andrés Gómez-De León
Low dose venetoclax plus itraconazole outpatient induction in newly diagnosed acute myeloid leukemia: A phase 2 study. Leukemia research 133 (2023)
Zhen-Yu Zhao, Nan Tang, Li-Er Lin
A rare BCR-ABL1 transcript in chronic myeloid leukemia: Case report and literature review. Leukemia research 133 (2023)
Fatima M Khadadah, Sonia Cerquozzi, Harold J Olney, Christina Fraga, Jill Dudebout, Anargyros Xenocostas, Nicholas Finn, Vincent Ethier, M Lynn Savoie, Lambert Busque, Kareem Jamani, Philip Kuruvilla, Carolyn Faught, Brian Leber, Rayan Kaedbey, Sarit E Assouline, Dennis Kim
Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy. Leukemia research 133 (2023)
Shinichi Kako, Shun-Ichi Kimura, Hidenori Wada, Yusuke Komiya, Hideki Nakasone, Masatoshi Sakurai, Jun Kato, Masatsugu Tanaka, Eriko Fujii, Takayoshi Tachibana, Wataru Yamamoto, Maki Hagihara, Reiko Watanabe, Akira Yokota, Hirofumi Nakano, Takehiko Mori, Chiaki Nakaseko, Heiwa Kanamori, Shinichiro Okamoto, Yoshinobu Kanda
Treatment strategy at the decision for allogeneic transplantation in patients with myelodysplastic syndrome in the era of azacitidine: A KSGCT prospective study. Leukemia research 133 (2023)
Syed J Mehdi, Kalyan Ghatak, Wen Ling, Sarah K Johnson, Joshua Epstein, Intawat Nookaew, Maurizio Zangari, Carolina Schinke, Sharmilan Thanendrarajan, Frits van Rhee, Shmuel Yaccoby
Growth and dormancy control of myeloma cells by mesenchymal stem cells. Leukemia research 133 (2023)
Stefan Nagel, Anja Fischer, Susanne Bens, Vivien Hauer, Claudia Pommerenke, Cord C Uphoff, Margarete Zaborski, Reiner Siebert, Hilmar Quentmeier
PI3K/AKT inhibitor BEZ-235 targets CCND2 and induces G1 arrest in breast implant-associated anaplastic large cell lymphoma. Leukemia research 133 (2023)
A Sherban, D Fredman, S Shimony, M Yeshurun, P Raanani, M Stahi, A Gafter-Gvili, O Wolach
Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML - A systematic review. Leukemia research 133 (2023)
Urmimala Bhattacharjee, Aditya Jandial, Charanpreet Singh, K S Lekshmon, Kundan Mishra, Rajeev Sandal, Ram Nampoothiri, Shano Naseem, Vanita Suri, Arihant Jain, Deepesh P Lad, Gaurav Prakash, Alka Khadwal, Pankaj Malhotra
Pregnancy and long-term outcomes of female patients with chronic myeloid leukemia on tyrosine kinase inhibitors who experienced unplanned pregnancies. Leukemia research 133 (2023)
Carolyn Owen, Sarah Eisinga, Versha Banerji, Nathalie Johnson, Alina S Gerrie, Andrew Aw, Christine Chen, Sue Robinson
Canadian evidence-based guideline for treatment of relapsed/refractory chronic lymphocytic leukemia. Leukemia research 133 (2023)
Muhlis Cem Ar, Riad El Fakih, Saule Gabbassova, Ahmad Alhuraiji, Fady Nasr, Ahmad Alsaeed, Nilgun Sayinalp, Mahmoud Marashi
Management of humoral secondary immunodeficiency in hematological malignancies and following hematopoietic stem cell transplantation: Regional perspectives. Leukemia research 133 (2023)
Mrinal M Patnaik
Clonal hematopoiesis of indeterminate potential: Overmedicalization or context dependant relevance? Leukemia research 133 (2023)
Daniel J Chandra, Curtis A Lachowiez
Anthracycline induced left ventricular dysfunction in AML: A focus on the molecularly defined future of cardio-oncology. Leukemia research 133 (2023)

volume 132, 2023

Andrew M Brunner, David Huggar, Ronda Copher, Zheng-Yi Zhou, Miriam L Zichlin, Annika Anderson, Nathaniel Downes, Ali McBride
Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: A retrospective study using the SEER-Medicare database. Leukemia research 132 (2023)
Maximilian Stahl, Gerard Giblin, Yiwen Liu, Eric S Winer, Jacqueline S Garcia, Evan Chen, Martha Wadleigh, Kelly Ling, R Coleman Lindsley, Shai Shimony, Kevin Copson, Anne Charles, Daniel J DeAngelo, Richard M Stone, Anju Nohria, Marlise R Luskin
Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia. Leukemia research 132 (2023)
Nil Albiol, Elionor Lynton-Pons, Olga Aso, Esther Moga, Silvia Vidal, Lucía Gómez-Pérez, Jose Alejandre Santiago, Mercè Triquell, Nerea Roch, Elisabeth Lázaro, Iria González, Joaquín López-Contreras, Albert Esquirol, Jorge Sierra, Rodrigo Martino, Irene García-Cadenas
mRNA-1273 SARS-CoV-2 vaccine in recently transplanted allogeneic hematopoietic cell transplant recipients: Dynamics of cellular and humoral immune responses and booster effect. Leukemia research 132 (2023)
Christian K Hirt, Nandan Padmanabha, Phillip D Michaels
Cohesin complex mutations in myeloid neoplasms are enriched for SRSF2, RUNX1, TET2, and NRAS co-mutations and morphologic dysplasia. Leukemia research 132 (2023)
Wenjie Xie, Zhichao Wang, Xiaofang Guo, Hongzai Guan
MiR-409-3p regulates the proliferation and apoptosis of THP-1 through targeting Rab10. Leukemia research 132 (2023)
Mohd Rizwan Shaikh, Bhumika Singh, Rohan Halder, Reema Singh, Mohd Riyan Shaikh, Narendra Agarwal, Nitin Bansal, Rayaz Ahmed, Sumeet Prakash Mirgh, Dinesh Bhurani
FLAG based v/s Standard 3 + 7 induction therapy in treatment naïve Acute Myeloid Leukemia: Time to think "beyond anthracyclines". Leukemia research 132 (2023)
Joseph M Brandwein, Kurt Ebeling, Lei Ding, Elena Liew, Nancy Zhu, Lauren Bolster, Marlene Hamilton, Mark Hnatiuk, Peng Wang
Changing frontline AML treatment patterns from 2013 to 2022. Leukemia research 132 (2023)
Nil Albiol, Elionor Lynton-Pons, Olga Aso, Esther Moga, Silvia Vidal, Lucía Gómez-Pérez, Jose Alejandre Santiago, Mercè Triquell, Nerea Roch, Elisabeth Lázaro, Iria González, Joaquín López-Contreras, Albert Esquirol, Jorge Sierra, Rodrigo Martino, Irene García-Cadenas
mRNA-1273 SARS-CoV-2 vaccine in recently transplanted allogeneic hematopoietic cell transplant recipients: Dynamics of cellular and humoral immune responses and booster effect. Leukemia research 132 (2023)
Błażej Ratajczak, Anna Przybyłowicz-Chalecka, Joanna Czerwińska-Rybak, Zuzanna Kanduła, Adam Ustaszewski, Lidia Gil, Krzysztof Lewandowski, Małgorzata Jarmuż-Szymczak
The presence of additional cytogenetic aberrations in chronic myeloid leukemia cells at the time of diagnosis or their appearance on tyrosine kinase inhibitor therapy predicts the imatinib treatment failure. Leukemia research 132 (2023)
Jie Liu, Afaf E G Osman, Kelly Bolton, Lucy A Godley
Germline predisposition to clonal hematopoiesis. Leukemia research 132 (2023)
Skyler Taylor, Guru Subramanian Guru Murthy, Lyndsey Runaas, Laura C Michaelis, Karen Carlson, Ehab L Atallah, Sameem M Abedin
Re-induction with venetoclax combinations or IDH inhibitors result in similar remission rates and lower treatment related morbidity among AML patients initially receiving intensive induction chemotherapy. Leukemia research 132 (2023)
Xinling Liu, Na Tang, Yong Liu, Jieting Fu, Yao Zhao, Haihua Wang, Haiying Wang, Zhenbo Hu
FOXK2 regulates PFKFB3 in promoting glycolysis and tumorigenesis in multiple myeloma. Leukemia research 132 (2023)
Jan-Michel Heger, Boris Böll, Jan-Hendrik Naendrup, Florian Simon, Claus Moritz Gräf, Michael Hallek, Alexander Shimabukuro-Vornhagen, Matthias Kochanek, Dennis A Eichenauer, Jorge Garcia Borrega
Hyperleukocytosis in patients with acute myeloid leukemia admitted to the intensive care unit: a single-center retrospective analysis. Leukemia research 132 (2023)

volume 131, 2023

Mariana Guarana, Marcio Nucci
Should patients with acute myeloid leukemia treated with venetoclax-based regimens receive antifungal prophylaxis? Leukemia research 131 (2023)
Hassan Tawhid Hassan
Antibody-drug conjugate [ADC] treatment of leukaemia. Leukemia research 131 (2023)